KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Supernus Pharmaceuticals (SUPN) Beginning Cash Balance: 2011-2025

Historic Beginning Cash Balance for Supernus Pharmaceuticals (SUPN) over the last 15 years, with Sep 2025 value amounting to $143.3 million.

  • Supernus Pharmaceuticals' Beginning Cash Balance rose 175.03% to $143.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $30.2 million, marking a year-over-year decrease of 68.18%. This contributed to the annual value of $75.1 million for FY2024, which is 19.40% down from last year.
  • Per Supernus Pharmaceuticals' latest filing, its Beginning Cash Balance stood at $143.3 million for Q3 2025, which was up 23.66% from $115.8 million recorded in Q2 2025.
  • Supernus Pharmaceuticals' 5-year Beginning Cash Balance high stood at $462.2 million for Q2 2023, and its period low was -$310.6 million during Q1 2023.
  • Over the past 3 years, Supernus Pharmaceuticals' median Beginning Cash Balance value was $69.3 million (recorded in 2025), while the average stood at $74.7 million.
  • Examining YoY changes over the last 5 years, Supernus Pharmaceuticals' Beginning Cash Balance showed a top increase of 299.43% in 2023 and a maximum decrease of 252.70% in 2023.
  • Over the past 5 years, Supernus Pharmaceuticals' Beginning Cash Balance (Quarterly) stood at $215.3 million in 2021, then slumped by 48.21% to $111.5 million in 2022, then fell by 14.81% to $95.0 million in 2023, then slumped by 66.65% to $31.7 million in 2024, then surged by 175.03% to $143.3 million in 2025.
  • Its last three reported values are $143.3 million in Q3 2025, $115.8 million for Q2 2025, and $69.3 million during Q1 2025.